These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25457497)

  • 1. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.
    Venkitaraman R; Lorente D; Murthy V; Thomas K; Parker L; Ahiabor R; Dearnaley D; Huddart R; De Bono J; Parker C
    Eur Urol; 2015 Apr; 67(4):673-9. PubMed ID: 25457497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.
    Mehra N; Sharp A; Lorente D; Dolling D; Sumanasuriya S; Johnson B; Dearnaley D; Parker C; de Bono J
    Clin Genitourin Cancer; 2017 Dec; 15(6):678-684.e1. PubMed ID: 28606735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer.
    Holder SL; Drabick J; Zhu J; Joshi M
    Cancer Biol Ther; 2015; 16(2):207-9. PubMed ID: 25756508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2 Randomized Controlled Trial of Personalized Peptide Vaccine Immunotherapy with Low-dose Dexamethasone Versus Dexamethasone Alone in Chemotherapy-naive Castration-resistant Prostate Cancer.
    Yoshimura K; Minami T; Nozawa M; Kimura T; Egawa S; Fujimoto H; Yamada A; Itoh K; Uemura H
    Eur Urol; 2016 Jul; 70(1):35-41. PubMed ID: 26782346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial.
    Tanaka N; Nishimura K; Okajima E; Ina K; Ogawa O; Nagata H; Akakura K; Fujimoto K; Gotoh M; Teramukai S; Hirao Y
    Jpn J Clin Oncol; 2017 Mar; 47(3):247-251. PubMed ID: 28042138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
    Fizazi K; Massard C; Bono P; Kataja V; James N; Tammela TL; Joensuu H; Aspegren J; Mustonen M
    Eur Urol Focus; 2017 Dec; 3(6):606-614. PubMed ID: 28753849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
    Rothermundt C; Hayoz S; Templeton AJ; Winterhalder R; Strebel RT; Bärtschi D; Pollak M; Lui L; Endt K; Schiess R; Rüschoff JH; Cathomas R; Gillessen S
    Eur Urol; 2014 Sep; 66(3):468-74. PubMed ID: 24412228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Tanaka N; Nishimura K; Okajima E; Ina K; Ogawa O; Nagata H; Akakura K; Fujimoto K; Gotoh M; Teramukai S; Hirao Y
    Int J Urol; 2019 Aug; 26(8):797-803. PubMed ID: 31055879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
    Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
    Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
    Noguchi M; Arai G; Egawa S; Ohyama C; Naito S; Matsumoto K; Uemura H; Nakagawa M; Nasu Y; Eto M; Suekane S; Sasada T; Shichijo S; Yamada A; Kakuma T; Itoh K
    Cancer Immunol Immunother; 2020 May; 69(5):847-857. PubMed ID: 32025848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
    Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Shiga KI; Koga H; Yamaguchi A; Naito S; Eto M
    BJU Int; 2016 Dec; 118(6):880-884. PubMed ID: 26991851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.
    Lorente D; Omlin A; Ferraldeschi R; Pezaro C; Perez R; Mateo J; Altavilla A; Zafeirou Z; Tunariu N; Parker C; Dearnaley D; Gillessen S; de Bono J; Attard G
    Br J Cancer; 2014 Dec; 111(12):2248-53. PubMed ID: 25314055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol.
    Shamash J; Powles T; Sarker SJ; Protheroe A; Mithal N; Mills R; Beard R; Wilson P; Tranter N; O'Brien N; McFaul S; Oliver T
    Br J Cancer; 2011 Feb; 104(4):620-8. PubMed ID: 21285990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
    Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
    Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI
    Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.
    Chadha MK; Tian L; Mashtare T; Payne V; Silliman C; Levine E; Wong M; Johnson C; Trump DL
    Cancer; 2010 May; 116(9):2132-9. PubMed ID: 20166215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.